Pyxis Oncology rises on FDA fast track tag for lead asset
Source: SeekingAlpha
2025-02-26 07:55:47 ET
Shares of Pyxis Oncology ( NASDAQ: PYXS ) traded higher in the premarket on Wednesday after the U.S. FDA issued its Fast Track Designation for the company’s lead candidate, PYX-201, targeted at head and neck cancer....
Read the full article on Seeking Alpha
For further details see:
Pyxis Oncology rises on FDA fast track tag for lead asset
Pyxis Oncology Inc.
NASDAQ: PYXS
PYXS Trading
1.28% G/L:
$1.525 Last:
141,174 Volume:
$1.54 Open:
PYXS Latest News
February 03, 2026 06:45:00 am
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
January 12, 2026 10:14:09 am
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
January 08, 2026 10:36:00 am
The $537B Precision Pivot: Why Molecular Monitoring is the New Oncology Standard
PYXS Stock Data
$126,496,274
71,256,534
0.76%
23
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
